| AAPS COVID Patient Treatment Guide (Oct. 2021) |
1.45 MB |
PDF |
2021/10/06 |
AAPS COVID Patient Treatment Guide (Oct. 2021) |
| Slides: Peter McCullough, MD at AAPS, Oct. 1, 2021 |
21.73 MB |
PDF |
2021/10/06 |
Slides: Peter McCullough, MD at AAPS, Oct. 1, 2021 |
| FDA Advisory Panel: COVID Boosters VTT subtitles (Sep. 17, 2021) |
521.53 KB |
VTT |
2021/09/23 |
FDA Advisory Panel: COVID Boosters VTT subtitles (Sep. 17, 2021) |
| Risk of Myocarditis from COVID-19 in People Under Age 20 (July 2021) |
155.21 KB |
PDF |
2021/09/22 |
Risk of Myocarditis from COVID-19 in People Under Age 20 (July 2021) |
| German Press conference: Death from vaccination/Undeclared components of COVID-19 vaccines (Sep. 20, 2021) |
187.15 KB |
VTT |
2021/09/22 |
German Press conference: Death from vaccination/Undeclared components of COVID-19 vaccines (Sep. 20, 2021) |
| Nanoscience and nanotechnologies: opportunities and uncertainties (2004) |
3.43 MB |
PDF |
2021/09/21 |
Nanoscience and nanotechnologies: opportunities and uncertainties (2004) |
| Graphene microsheets enter cells through membrane penetration (2013) |
693.54 KB |
PDF |
2021/09/21 |
Graphene microsheets enter cells through membrane penetration (2013) |
| CDC: Trends in BMI Before/During COVID-19 Pandemic (Sep 2021) |
773.90 KB |
PDF |
2021/09/20 |
CDC: Trends in BMI Before/During COVID-19 Pandemic (Sep 2021) |
| Aerosol transmission is important mode of influenza spread (2013) |
251.67 KB |
PDF |
2021/09/20 |
Aerosol transmission is important mode of influenza spread (2013) |
| UK: Self-reported real-world safety, reactogenicity of COVID-19 vaccines |
951.97 KB |
PDF |
2021/09/20 |
UK: Self-reported real-world safety, reactogenicity of COVID-19 vaccines |
| Six Month Safety and Efficacy of Pfizer mRNA COVID-19 Vaccine |
647.70 KB |
PDF |
2021/09/20 |
Six Month Safety and Efficacy of Pfizer mRNA COVID-19 Vaccine |
| NEJM: mRNA Vaccines in pregnant women (Sep. 2021 correction) |
2.03 MB |
PDF |
2021/09/20 |
NEJM: mRNA Vaccines in pregnant women (Sep. 2021 correction) |
| mRNA COVID-19 vaccination and confirmed Myopericarditis |
1.03 MB |
PDF |
2021/09/20 |
mRNA COVID-19 vaccination and confirmed Myopericarditis |
| Mask mandate use and efficacy (May 2021) |
787.44 KB |
PDF |
2021/09/20 |
Mask mandate use and efficacy (May 2021) |
| COVID Mortality Overestimation |
363.98 KB |
PDF |
2021/09/20 |
COVID Mortality Overestimation |
| JAMA: Household Transmission of COVID-19 (Symptomatic/Asymptomatic) |
1.42 MB |
PDF |
2021/09/20 |
JAMA: Household Transmission of COVID-19 (Symptomatic/Asymptomatic) |
| BMJ: Menstrual changes after COVID-19 Vaccination |
147.45 KB |
PDF |
2021/09/20 |
BMJ: Menstrual changes after COVID-19 Vaccination |
| Open Letter to the EMA and European Parliament from Doctors for COVID ethics |
507.91 KB |
PDF |
2021/09/20 |
Open Letter to the EMA and European Parliament from Doctors for COVID ethics |
| Lazarus Report: Vaccine Adverse Event Reporting System (2011) |
96.19 KB |
PDF |
2021/09/20 |
Lazarus Report: Vaccine Adverse Event Reporting System (2011) |
| FDA Advisory Panel: Briefing, Pfizer Boosters (Sep. 17, 2021) |
301.12 KB |
PDF |
2021/09/20 |
FDA Advisory Panel: Briefing, Pfizer Boosters (Sep. 17, 2021) |
| Study: Vaccinated spread infectious COVID |
1.83 MB |
PDF |
2021/09/16 |
Study: Vaccinated spread infectious COVID |
| mRNA vaccine associated myocarditis in children, ages 12-17 (Aug. 30, 2021) |
829.07 KB |
PDF |
2021/09/12 |
mRNA vaccine associated myocarditis in children, ages 12-17 (Aug. 30, 2021) |
| COVID-19 spike proteins, cardiac cells, and microvascular disease (July 2021) |
2.14 MB |
PDF |
2021/09/07 |
COVID-19 spike proteins, cardiac cells, and microvascular disease (July 2021) |
| Lancet: Particle sizes of infection aerosols (Fennelly, July 2020) |
441.03 KB |
PDF |
2021/09/01 |
Lancet: Particle sizes of infection aerosols (Fennelly, July 2020) |
| Ivermectin for Prevention and Treatment of COVID-19 Infection (August 2021) |
2.62 MB |
PDF |
2021/09/01 |
Ivermectin for Prevention and Treatment of COVID-19 Infection (August 2021) |
| Uncanny similarity of unique inserts in COVID-19 spike protein to HIV-1 (Jan. 2020) |
3.24 MB |
PDF |
2021/09/01 |
Uncanny similarity of unique inserts in COVID-19 spike protein to HIV-1 (Jan. 2020) |
| FDA: Fact sheet for providers administering Moderna COVID-19 vaccine (Aug. 2021) |
308.98 KB |
PDF |
2021/09/01 |
FDA: Fact sheet for providers administering Moderna COVID-19 vaccine (Aug. 2021) |
| Six Month Safety and Efficacy of Pfizer vaccine, supplement (July 2021) |
647.73 KB |
PDF |
2021/09/01 |
Six Month Safety and Efficacy of Pfizer vaccine, supplement (July 2021) |
| Six Month Safety and Efficacy of Pfizer vaccine (July 2021) |
587.05 KB |
PDF |
2021/09/01 |
Six Month Safety and Efficacy of Pfizer vaccine (July 2021) |
| Effectiveness of masks to prevent SARS-CoV-2 in Danish mask wearers (Mar. 2021) |
683.99 KB |
PDF |
2021/09/01 |
Effectiveness of masks to prevent SARS-CoV-2 in Danish mask wearers (Mar. 2021) |
| FDA briefing: Moderna COVID-19 vaccine (Dec. 2020) |
701.38 KB |
PDF |
2021/09/01 |
FDA briefing: Moderna COVID-19 vaccine (Dec. 2020) |
| FDA briefing: Pfizer COVID-19 Vaccine (Dec. 2020) |
1.13 MB |
PDF |
2021/09/01 |
FDA briefing: Pfizer COVID-19 Vaccine (Dec. 2020) |
| SARS-like bat coronaviruses shows potential for human emergence (2015) |
963.10 KB |
PDF |
2021/09/01 |
SARS-like bat coronaviruses shows potential for human emergence (2015) |
| Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after (June 2021) |
24.13 MB |
PDF |
2021/09/01 |
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after (June 2021) |
| Age dependent immune response to Pfizer COVID-19 vaxx (March 2021) |
206.95 KB |
PDF |
2021/09/01 |
Age dependent immune response to Pfizer COVID-19 vaxx (March 2021) |
| Immunity & Aging/Immunosenescence and Vaccination |
206.95 KB |
PDF |
2021/09/01 |
Immunity & Aging/Immunosenescence and Vaccination |
| Fauci: Emerging pandemic diseases, how we got to COVID-19 |
3.19 MB |
PDF |
2021/08/31 |
Fauci: Emerging pandemic diseases, how we got to COVID-19 |
| Masks don't work: a review of science relevant to COVID-19 social policy |
388.04 KB |
PDF |
2021/08/31 |
Masks don't work: a review of science relevant to COVID-19 social policy |
| NVSS: Guidance for certifying deaths due to COVID-19 (April 2020) |
297.13 KB |
PDF |
2021/08/31 |
NVSS: Guidance for certifying deaths due to COVID-19 (April 2020) |
| CDC: Use of cloth face coverings to help slow the spread of COVID-19 (2020) |
756.94 KB |
PDF |
2021/08/31 |
CDC: Use of cloth face coverings to help slow the spread of COVID-19 (2020) |
| HHS: Deaths due to lethal force by law enforcement 2009-2012 (2016) |
412.65 KB |
PDF |
2021/08/31 |
HHS: Deaths due to lethal force by law enforcement 2009-2012 (2016) |
| CDC MMWR: Community mitigation guidelines to prevent pandemic influenza (2017) |
899.24 KB |
PDF |
2021/08/31 |
CDC MMWR: Community mitigation guidelines to prevent pandemic influenza (2017) |
| Respirator and mask effectiveness against respiratory infections (2016) |
522.89 KB |
PDF |
2021/08/31 |
Respirator and mask effectiveness against respiratory infections (2016) |
| Aerosol leakage through N95 respirators and surgical masks (2015) |
2.00 MB |
PDF |
2021/08/31 |
Aerosol leakage through N95 respirators and surgical masks (2015) |
| Face mask and control of respiratory virus transmission in households (2009) |
222.43 KB |
PDF |
2021/08/31 |
Face mask and control of respiratory virus transmission in households (2009) |
| PPE and antivirals during hospitalization for suspected avian or pandemic influenza (2007) |
294.37 KB |
PDF |
2021/08/31 |
PPE and antivirals during hospitalization for suspected avian or pandemic influenza (2007) |
| Public health interventions and SARS spread 2003 (2004) |
201.96 KB |
PDF |
2021/08/31 |
Public health interventions and SARS spread 2003 (2004) |
| CDC: Recommendations for facemask and respirators where H1N1 transmission is detected (2009) |
77.38 KB |
PDF |
2021/08/31 |
CDC: Recommendations for facemask and respirators where H1N1 transmission is detected (2009) |
| CDC: Randomized controlled trial of hand washing and face masks to reduce influenza transmission (2011) |
256.00 KB |
PDF |
2021/08/31 |
CDC: Randomized controlled trial of hand washing and face masks to reduce influenza transmission (2011) |
| CDC: Influenza Virus Aerosols in Human Breath: Particle Size, Effect of Surgical Masks (2015) |
3.92 MB |
PDF |
2021/08/31 |
CDC: Influenza Virus Aerosols in Human Breath: Particle Size, Effect of Surgical Masks (2015) |
| CDC: Pandemic Planning Guidance (2017) |
899.24 KB |
PDF |
2021/08/31 |
CDC: Pandemic Planning Guidance (2017) |
| CDC: Pandemic Planning Guidance (2007) |
2.51 MB |
PDF |
2021/08/31 |
CDC: Pandemic Planning Guidance (2007) |
| Imperial College Report: Impact of NPIs to reduce COVID-19 mortality (March 2020) |
721.33 KB |
PDF |
2021/08/31 |
Imperial College Report: Impact of NPIs to reduce COVID-19 mortality (March 2020) |
| WHO non-pharmaceutical public health measures for mitigating epidemic and pandemic influenza (2019) |
1.37 MB |
PDF |
2021/08/31 |
WHO non-pharmaceutical public health measures for mitigating epidemic and pandemic influenza (2019) |
| Chloroquine is a potent inhibitor of SARS coronavirus infection and spread (2005) |
847.81 KB |
PDF |
2021/08/27 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread (2005) |
